Surveillance of Pseudomonas aeruginosa in intensive care units: Clusters of nosocomial cross-infection and encounter of a multiple-antibiotic resistant strain

Chemotherapy

Volumn 44, Issue 4, 1998, Pages 243-259

  Traub, Walter H ^a   Scheidhauer, Ralf ^a   Leonhard, Birgit ^a   Bauer, Dierk ^a  

^a SAARLAND UNIVERSITY   (Germany)

Author keywords

Amikacin; Antibiotic susceptibility; Aztreonam; Bactericidal activity; Bacteriocin typing; Ceftazidime; Defibrinated human blood; Fosfomycin; Macrorestriction genomic DNA analysis; Minimal bactericidal concentrations; Minimal inhibitory concentrations; Multiple antibiotic resistance; Polymyxin B; Pseudomonas aeruginosa; Pulsed field gel electrophoresis; Rifampin; Serogrouping

Indexed keywords

AMIKACIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; AZTREONAM; BACTERIAL DNA; CEFAZOLIN; CEFEPIME; CEFOTAXIME; CEFTAZIDIME; CEFUROXIME; CHLORAMPHENICOL; CIPROFLOXACIN; COTRIMOXAZOLE; DOXYCYCLINE; FOSFOMYCIN; GENTAMICIN; IMIPENEM; MEROPENEM; NALIDIXIC ACID; NETILMICIN; NORFLOXACIN; OFLOXACIN; PIPERACILLIN; POLYMYXIN B; RIFAMPICIN; SULTAMICILLIN; TIMENTIN; TOBRAMYCIN;

AGAR GEL DIFFUSION; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERICIDAL ACTIVITY; CONTROLLED STUDY; CROSS INFECTION; DNA DETERMINATION; HOSPITAL INFECTION; HUMAN; INTENSIVE CARE; MAJOR CLINICAL STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; PULSED FIELD GEL ELECTROPHORESIS; SEROTYPING;

ANTI-BACTERIAL AGENTS; BACTERIOCINS; CROSS INFECTION; DRUG RESISTANCE, MULTIPLE; HUMANS; INTENSIVE CARE UNITS; MICROBIAL SENSITIVITY TESTS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; SEROTYPING;

EID: 0031780816     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000007121     Document Type: Article

References (82)

1. Holloway BW, Römling U, Tümmler B: Genomic mapping of Pseudomonas aeruginosa PAO. Microbiology 1994;140:2907-2929.
2. Kersters K, Ludwig W, Vancanneyt M, De Vos P, Gills M, Schleifer K-H: Recent changes in the classification of the pseudomonads: An overview. Syst Appl Microbiol 1996;19: 465-477.
3. Body GP, Bolivar R, Fainstein V, Jadeja L: Infections caused by Pseudomonas aeruginosa. Rev Infect Dis 1983;5:279-313.
4. Bodey GP, Jadeja L, Elting L: Pseudomonas bacteremia. Retrospective analysis of 410 episodes. Arch Intern Med 1985;145:1621-1629.
5. Gould IM, Wise R: Pseudomonas aeruginosa: Clinical manifestations and management. Lancet 1985;ii: 1224-1227.
6. Botzenhart K, Rüden H: Hospital infections caused by Pseudomonas aeruginosa; in Döring G, Holder IA, Botzenhart K (eds): Basic Research and Clinical Aspects of Pseudomonas aeruginosa. Antibiot Chemother. Basel, Karger, 1987, vol 39, pp 1-15.
7. Moss RB: Cystic fibrosis: Pathogenesis, pulmonary infection, and treatment. Clin Infect Dis 1995;21:839-851.
8. Govan JRW, Deretic V: Microbial pathogenesis in cystic fibrosis: Mucoid Pseudomonas aeruginosa and Burkholderia cepacia. Microbiol Rev 1996;60:539-574.
9. Olson B, Weinstein RA, Nathan C, Chamberlin W, Kabins SA: Epidemiology of endemic Pseudomonas aeruginosa: Why infection control efforts have failed. J Infect Dis 1984;150:808-816.
10. Widmer AF, Wenzel RP, Trilla A, Bale MJ, Jones RN, Doebbeling BN: Outbreak of Pseudomonas aeruginosa infections in a surgical intensive care unit: Probable transmission via hands of a health care worker. Clin Infect Dis 1993;16:372-376.
11. Vazquez F, Mendoza MC, Villar MH, Vindel A, Mendez FJ: Characteristics of Pseudomonas aeruginosa strains causing septicemia in a Spanish hospital 1981-1990. Eur J Clin Microbiol Infect Dis 1992;11:698-703.
12. Buret A, Cripps AW: The immunoevasive activities of Pseudomonas aeruginosa. Relevance for cystic fibrosis. Am Rev Respir Dis 1993; 148:793-805.
13. Feldman M, Bryan R, Rajan S, Scheffler L, Brunnert S, Tang H, Prince A: Role of flagella in pathogenesis of Pseudomonas aeruginosa pulmonary infection. Infect Immun 1998;66:43-51.
14. Kronberg G: Lipopolysaccharide (LPS), LPS-immune complexes and cytokines as inducers of pulmonary inflammation in patients with cystic fibrosis and chronic Pseudomonas aeruginosa lung infection. APMIS 1995;103(suppl 50):1-30.
15. Archibald L, Phillips L, Monnet D, McGowan JE Jr, Tenover F, Gaynes R: Antimicrobial resistance in isolates from inpatients and outpatients in the United States: Increasing importance of the intensive care unit. Clin Infect Dis 1997;24:211-215.
16. Bert F, Lambert-Zechovsky N: Comparative distribution of resistance patterns and serotypes in Pseudomonas aeruginosa isolates from intensive care units and other wards. J Antimicrob Chemother 1996;37:809-813.
17. Bert F, Lambert-Techovsky N: Antibiotic resistance patterns in Pseudomonas aeruginosa: An 8-year surveillance study in a French hospital. Int J Antimicrob Agents 1997;9: 107-112.
18. Courvalin P: Evasion of antibiotic action by bacteria. J Antimicrob Chemother 1996;37:855-869.
19. Gold HS, Moellering RC: Antimicrobial-drug resistance. N Engl J Med 1996;335:1445-1453.
20. Pitt TL, Livermore DM, Miller G, Vatopoulos A, Legakis NJ: Resistance mechanisms of multiresistant serotype O12 Pseudomonas aeruginosa isolated in Europe. J Antimicrob Chemother 1990;26:319-328.
21. Chen HY, Yuan M, Livermore DM: Mechanism of resistance to β-lactam antibiotics amongst Pseudomonas aeruginosa isolates collected in the UK in 1993. J Med Microbiol 1995;43:300-309.
22. Bush K, Jacoby GA, Medeiros AA: A functional classification scheme for β-lactamases and its correlation with molecular structure. Antimicrob Agents Chemother 1995;39: 1211-1233.
23. Danel F, Hall LMC, Gur D, Livermore DM: Oxa-15, an extended-spectrum variant of OXA-1 β-lactamase, isolated from a Pseudomonas aeruginosa strain. Antimicrob Agents Chemother 1997;41:785-790.
24. Davies J: Inactivation of antibiotics and the dissemination of resistance genes. Science 1994;264:375-381.
25. Miro E, Navarro F, March F, Sanchez F, Mirelis B: Emergence of different resistance mechanisms in Pseudomonas aeruginosa in a patient treated with imipenem. Eur J Clin Microbiol Infect Dis 1995;14: 731-732.
26. Spratt BG: Resistance to antibiotics mediated by target alterations. Science 1994;264:388-393.
27. Sumita Y, Fukasawa M: Meropenem resistance in Pseudomonas aeruginosa. Chemotherapy 1996;42:47-56.
28. Nikaido H: Prevention of drug access to bacterial targets: Permeability barriers and active efflux. Science 1994;264:382-388.
29. Masuda N, Ohya S: Cross-resistance to meropenem, cephems, and quinolones in Pseudomonas aeruginosa. Antimicrob Agents Chemother 1992;36:1847-1851.
30. Li X-Z, Ma D, Livermore DM, Nikaido H: Role of efflux pump(s) in intrinsic resistance of Pseudomonas aeruginosa: Active efflux as a contributing factor to β-lactam resistance. Antimicrob Agents Chemother 1994;38:1742-1752.
31. Poole K.: Bacterial multidrug resistance - Emphasis on efflux mechanisms and Pseudomonas aeruginosa. J Antimicrob Chemother 1994; 34:453-456.
32. Nikaido H: Multidrug efflux pumps of Gram-negative bacteria. J Bacteriol 1996;178:5833-5859.
33. Köhler T, Michea-Hamzehpour M, Plesiat P, Kahr A-L, Pechere J-C: Differential selection of multidrug efflux systems by quinolones in Pseudomonas aeruginosa. Antimicrob Agents Chemother 1997;41: 2540-2543.
34. Xiong Y-Q, Caillon J, Kergueris MF, Drugeon H, Baron D, Potel G, Bayer AS: Adaptive resistance of Pseudomonas aeruginosa induced by aminoglycosides and killing kinetics in a rabbit endocarditis model. Antimicrob Agents Chemother 1997;41:823-826.
35. Karlowsky JA, Hoban DJ, Zelenitsky SA, Zhanel GG: Altered denA and anr gene expression in aminoglycoside adaptive resistance in Pseudomonas aeruginosa. J Antimicrob Chemother 1997;40:371-376.
36. Yonezawa M, Takahata M, Matsubara N, Watanabe Y, Narita H: DNA gyrase gyrA mutations in quinolone-resistant clinical isolates of Pseudomonas aeruginosa. Antimicrob Agents Chemother 1995;39: 1970-1972.
37. Pina SE, Mattingly SJ: The role of fluorequinolones in the promotion of alginate synthesis and antibiotic resistance in Pseudomonas aeruginosa. Curr Microbiol 1997;35:103-108.
38. Martinez JL, Blazquez J, Baquero F: Non-canonical mechanisms of antibiotic resistance. Eur J Clin Microbiol Infect Dis 1994;13:1015-1022.
39. Walia S, Madhavan T, Williamson T, Kaiser A, Tewari R: Protein patterns, serotyping and plasmid DNA profiles in the epidemiologic finger-printing of Pseudomonas aeruginosa. Eur J Clin Microbiol Infect Dis 1988;7:248-255.
40. Liu PV, Matsumoto H, Kusama H, Bergan T: Survey of heat-stable, major somatic antigens of Pseudomonas aeruginosa. Int J Syst Bacteriol 1983;33:256-264.
41. Pitt TL: Epidemiological typing of Pseudomonas aeruginosa. Eur J Clin Microbiol Infect Dis 1988;7:238-247.
42. The International Pseudomonas aeruginosa Typing Study Group: A multicenter comparison of methods for typing strains of Pseudomonas aeruginosa predominantly from patients with cystic fibrosis. J Infect Dis 1994;169:134-142.
43. Bergan T: Phage typing of Pseudomonas aeruginosa; in Bergan T, Norris JR (eds): Methods in Microbiology. London, Academic Press, 1978, vol 10, pp 169-199.
44. Charnock C, Bergan T: Multilocus enzyme electrophoresis of major O-antigen reference strains of Pseudomonas aeruginosa. Eur J Clin Microbiol Infect Dis 1992;11:810-816.
45. Grattard F, Gaudin OG, Pozzetto B, Ros A, Mbida AD: Genotypic homogeneity of nosocomial Pseudomonas aeruginosa O12 strains demonstrated by analysis of protein profiles, DNA fingerprints and rRNA gene restriction patterns. Eur J Clin Microbiol Infect Dis 1993;12:57-61.
46. Poh CL, Yeo CC: Recent advances in typing of Pseudomonas aeruginosa. J Hosp Infect 1993;24:175-181.
47. Kobayashi I, Hasegawa M, Miyazaki S, Nishida M, Goto S: In vitro and in vivo changes of serotype in Pseudomonas aeruginosa isolates by anti-pseudomonal drugs. J Antibiot 1994;47:72-79.
48. Renders N, van Belkum A, Barth A, Goessens W, Mounton J, Verbrugh H: Typing of Pseudomonas aeruginosa strains from patients with cystic fibrosis: Phenotyping versus genotyping. Clin Microbiol Infect 1996;1:261-265.
49. Garaizar J, Latorre M, Lopez-Molina N, Laconcha I, Alberdi L, Rementeria A, Audicana A, Uliarte R, Cisterna R: Computerized restriction endonuclease analysis compared with O-serotype and phage type in the epidemiologic fingerprinting of Pseudomonas aeruginosa strains. Clin Microbiol Infect 1997; 3:222-228.
50. Grattard F, Pozzetto B, Ros A, Gaudin OG: Differentiation of Pseudomonas aeruginosa strains by ribotyping: High discriminatory power by using a single restriction endonuclease. J Med Microbiol 1994;40: 275-281.
51. Poh CL, Yeo CC, Tay L: Genome fingerprinting by pulsed-field gel electrophoresis and ribotyping to differentiate Pseudomonas aeruginosa serotype Oil strains. Eur J Clin Microbiol Infect Dis 1992;11: 817-822.
52. Martin C, Ichou MA, Massicot P, Goudeau A, Quentin R: Genetic diversity of Pseudomonas aeruginosa strains isolated from patients with cystic fibrosis revealed by restriction fragment length polymorphism of the rRNA gene region. J Clin Microbiol 1995;33:1461-1466.
53. Kersulyte D, Struelens MJ, Deplano A, Berg DE: Comparison of arbitrarily primed PCR and macrorestriction (pulsed-field gel electrophoresis) typing of Pseudomonas aeruginosa strains from cystic fibrosis patients. J Clin Microbiol 1995;33: 2216-2219.
54. Grundmann H, Schneider C, Hartung D, Daschner FD, Pitt TL: Discriminatory power of three DNA-based typing techniques for Pseudomonas aeruginosa . J Clin Microbiol 1995;33:528-534.
55. Nociari MM, Catalano M, Garcia DC, Copenhaver SC, Vasil ML, Sordelli DO: Comparative usefulness of ribotyping, exotoxin A genotyping, and SalI restriction fragment length polymorphism analysis for Pseudomonas aeruginosa lineage assessment. Diagn Microbiol Infect Dis 1996;24:179-190.
56. Döring G, Hörz M, Ortelt J, Grupp H, Wolz C: Molecular epidemiology of Pseudomonas aeruginosa in an intensive care unit. Epidemiol Infect 1993;110:427-436.
57. Bingen E, Bonarcorsi S, Rohrlich P, Duval M, Lhopital S, Brahimi N, Vilmer E, Goering RV: Molecular epidemiology provides evidence of genotypic heterogeneity of multidrug-resistant Pseudomonas aeruginosa serotype O:12 outbreak isolates from a pediatric hospital. J Clin Microbiol 1996;34:3226-3229.
58. Renders N, Römling U, Verbrugh H, van Belkum A: Comparative typing of Pseudomonas aeruginosa by random amplification of polymorphic DNA or pulsed-field gel electrophoresis of DNA macrorestriction fragments. J Clin Microbiol 1996;34:3190-3195.
59. Grundmann H, Schneider C, Daschner D: Fluorescence-based DNA fingerprinting elucidates nosocomial transmission of phenotypically variable Pseudomonas aeruginosa in intensive care units. Eur J Clin Microbiol Infect Dis 1995;14: 1057-1062.
60. Hernandez J, Ferrus MA, Hernandez M, Owen RJ: Arbitrary primed PCR fingerprinting and serotyping of clinical Pseudomonas aeruginosa strains. FEMS Immunol Med Microbiol 1977;17:37-47.
61. Traub WH, Spohr M, Bauer D: Pseudomonas aeruginosa: In vitro susceptibility to antimicrobial drugs, single and combined, with and without defibrinated human blood. Chemotherapy 1988;34:284-297.
62. Traub WH, Raymond EA, Startsman TS: Bacteriocin (marcescin) typing of clinical isolates of Serratia marcescens. Appl Microbiol 1971; 21:837-840.
63. Allardet-Servent A, Bouziges N, Carles-Nurit M-J, Bourg G, Gouby A, Ramuz M: Use of low-frequency-cleavage restriction endonucleases for DNA analysis in epidemiological investigations of nosocomial bacterial infections. J Clin Microbiol 1989;27:2057-2061.
64. Gilligan PH: Pseudomonas and Burkholderia; in Murray PR, Baron EJ, Pfaller MA, Tenover FC, Yolken RH (eds): Manual of Clinical Microbiology, ed 6. Washington, American Society for Microbiology, 1995, pp 509-519.
65. Traub WH, Fukushima P: Serotyping of Serratia marcescens: Simplified tube O-agglutination test and comparison with other serological procedures. Zentralbl Bakteriol Hyg 1979;A244:474-493.
66. Smith CL, Cantor CR: Purification, specific fragmentation, and separation of large DNA molecules. Methods Enzymol 1987;155:449-467.
67. Traub WH, Eiden A, Leonhard B, Bauer D: Typing of nosocomial strains of Serratia marcescens: Comparison of restriction enzyme cleaved genomic DNA fragment (PFGE) analysis with bacteriocin typing, biochemical profiles and serotyping. Zentralbl Bakteriol 1996; 284:93-106.
68. 67a Guide to Genome Analysis and Mapping. Mannheim, Boehringer Mannheim, 1993, pp 1-32.
69. Tenover FC, Arbeit RD, Goering RV, Mickelsen PA, Murray BE, Persing DH, Swaminathan B: Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: Criteria for bacterial strain typing. J Clin Microbiol 1995;33:2233-2239.
70. Bauer AW, Kirby WMM, Sherris JC, Turck M: Antibiotic susceptibility testing by a standardized single disk method. Am J Clin Pathol 1966;45:493-496.
71. National Committee for Clinical Laboratory Standards: Performance Standards for Antimicrobial Disk Susceptibility tests, ed 6. Villanova, NCCLS, 1997, NCCLS document M2-A6.
72. National Committee for Clinical Laboratory Standards: Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically, ed 3. Villanova, NCCLS, 1993, NCCLS document M7-A3.
73. Woods DE, Lam JS, Paranchych W, Speert DP, Campbell M, Godfrey AJ: Correlation of Pseudomonas aeruginosa virulence factors from clinical and environmental isolates with pathogenicity in the neutropenic mouse. Can J Microbiol 1997;43: 541-551.
74. Tessier F, Quentin C: In vitro activity of fosfomycin combined with ceftazidime, imipenem, amikacin, and ciprofloxacin against Pseudomonas aeruginosa. Eur J Clin Microbiol Infect Dis 1997;16:159-162.
75. Bayer AS, Norman D, Kim KS: Efficacy of amikacin and ceftazidime in experimental aortic valve endocarditis due to Pseudomonas aeruginosa. Antimicrob Agents Chemother 1985;28:781-785.
76. Yu VL, Zuravleff JJ, Peacock JE, De Hertogh D, Tashjian L: Addition of rifampin to carboxypenicillin-aminoglycoside combination for the treatment of Pseudomonas aeruginosa infection: Clinical experience with four patients. Antimicrob Agents Chemother 1984;26:575-577.
77. Kumon H, Ono N, Iida M, Nickel JC: Combination effect of fosfomycin and ofloxacin against Pseudomonas aeruginosa. Antimicrob Agents Chemother 1995;39:1038-1044.
78. Cappelletty DM, Rybak MJ: Comparision of methodologies for synergism testing of drug combinations against resistant strains of Pseudomonas aeruginosa. Antimicrob Agents Chemother 1996;40:677-683.
79. Arbeit RD: Laboratory procedures for the epidemiologic analysis of microorganisms; in Murray PR, Baron EJ, Pfaller MA, Tenover FC, Yolken RH (eds): Manual of Clinical Microbiology, ed 6. Washington, American Society for Microbiology, 1995, pp 190-208.
80. Elaichouni A, Verschraegen G, Claeys G, Devleeschouwer M, Godard C, Vaneechoutte M: Pseudomonas aeruginosa serotype O12 outbreak studied by arbitrary primer PCR. J Clin Microbiol 1994;32: 666-671.
81. Neu HC: The crisis in antibiotic resistance. Science 1992;257:1064-1073.
82. Troillet N, Samore MH, Carmeli Y: Imipenem-resistant Pseudomonas aeruginosa: Risk factors and antibiotic susceptibility patterns. Clin Infect Dis 1997;25:1094-1098.